Skip to main content
Clinical Trials/EUCTR2017-002485-40-IT
EUCTR2017-002485-40-IT
Active, not recruiting
Phase 1

TREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT) - REBOOT

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III0 sites8,468 target enrollmentJanuary 15, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
STEMI or NSTEMI patients being discharged from the index hospitalization with a LVEF>40% without previous heart failure
Sponsor
CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III
Enrollment
8468
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 15, 2021
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III

Eligibility Criteria

Inclusion Criteria

  • 1\) \> 18 years old or 18 years old
  • 2\) STEMI or STEMI patient
  • 3\) LVEF \>40%
  • 4\) INFORM CONSENT SIGNED
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 2000
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 6468

Exclusion Criteria

  • 1\) Known allergy or intolerance to beta\-blockers
  • 2\) Absolute contraindication to beta\-blocker therapy according to treating physician judge
  • 3\) Prior history of HF, Killip class on admission or during hospitalization \= II
  • 4\) Severe valvular heart disease (\> 3\+ for aortic or mitral insufficiency, aortic or mitral valve area \=1\.0 cm2\).
  • 5\) Any condition (appart from AMI) that requires beta\-blocker prescription on discharge according to treating physician judge
  • 6\) Any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year),
  • 7\) Patients participating in other clinical trials.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
BETAMI studien: Behandling med eller uten betablokkere hos pasientermed hjerteinfarktPatients admitted to hospital with acute myocardial infarction treated With reperfusion therapy (i.e trombolysis or percutaneous coronary intervention)Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2018-000590-75-NOOslo University Hospital5,000
Completed
Phase 4
TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"Myocardial Infarction
NCT03596385Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III8,505
Active, not recruiting
Phase 1
Danish trial of beta blocker treatment after myocardial infarction without signs of heart failure (DANBLOCK)MedDRA version: 20.0Level: LLTClassification code 10028595Term: Myocardial infarctSystem Organ Class: 10007541 - Cardiac disordersMyocardial infarction. We wish to test whether long-term treatment with betablocker (bisoprolol, carvedilol, metoprolol or nebivolol) leads to better prognosis than no treatment in patients suffering a myocardial infarction who do not have signs of heart failureTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2018-002699-42-DKBispebjerg Frederiksberg Hospital2,760
Active, not recruiting
Phase 4
BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic FunctionAcute Myocardial InfarctionNon-ST Elevation Myocardial InfarctionST Elevation Myocardial Infarction
NCT03646357Oslo University Hospital2,895
Active, not recruiting
Phase 1
Evaluation of Beta Blockers for the Treatment of Asthma. A randomised controlled trial of propranolol.asthmaMedDRA version: 12.1Level: LLTClassification code 10003553Term: Asthma
EUCTR2009-017356-28-GBniversity of Dundee15